elldex Therapeutics (NASDAQ:CLDX) investors got crushed earlier this year when the company’s lead drug candidate fell short in late-stage studies, but a wave of news in the coming year could reignite investor interest and send shares soaring again.
Digging around the bargain bin
Celldex Therapeutics was a high-flyer in 2015 when positive mid-stage study results for Rintega, a drug targeting a tough-to-treat brain cancer known as glioblastoma, kick-started optimism that an eventual approval could reshape treatment.
